Rheumatology News

Physicians treating Medicare patients are staring down the barrel of five consecutive years of cuts to their reimbursement rates.

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or prostate cancer, according to data published in The Lancet Rheumatology.

It has been 5 years since the start of the COVID-19 pandemic, which forced many providers to embrace telehealth.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy alone, according to data.

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson.

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

Patients with osteoarthritis, but not immune-related arthritis, demonstrate increased odds for developing overactive bladder vs. those without, according to data spanning 15 years published in Science Reports.

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.